MedTrace Logo

Ocrelizumab Access by Socio-Economic Status

NCT05131984 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2025-11-24

No results posted yet for this study

Summary

The primary aim of this project is to determine whether there are differences in access to, efficacy and tolerability of Ocrelizumab in men and women of different racial and ethnic origins and socio-economic backgrounds with RRMS and PPMS in two large academic MS Centers with a high volume of patients on Ocrelizumab. The study is a retrospective analysis of multiple sclerosis patients cared for at Brigham and Women's Hospital and Boston Medical Center who were treated with Ocrelizumab during the 4 year study period.

Conditions

Interventions

DRUG

Ocrelizumab

At least 3 treatments (two loading treatments of 300mg each, and one full dose treatment of 600 mg over the course of 1 year

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Boston Medical Center

    collaborator OTHER

  • Brigham and Women's Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-18
Primary Completion
2023-07-01
Completion
2023-07-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05131984 on ClinicalTrials.gov